Advanced search
Publication Cover
Baylor University Medical Center Proceedings
The peer-reviewed journal of Baylor Scott & White Health
Volume 15, 2002 - Issue 3
Submit an article Journal homepage
61
Views
0
CrossRef citations to date
0
Altmetric
Third in a series on molecular approaches in oncology

New Modalities in Oncology: Ribozymes

C. Casey CunninghamCorrespondence[email protected]
, MD
Pages 247-249 | Published online: 11 Dec 2017

  • Zaug AJ, Cech TR. The intervening sequence RNA of Tetrahymena is an enzyme. Science 1986;231: 470–475.
  • Pley HW, Flaherty KM, McKay DB. Three-dimensional structure of a hammerhead ribozyme. Nature 1994;372: 68–74.
  • Birikh KR, Heaton PA, Eckstein F. The structure, function and application of the hammerhead ribozyme. Eur J Biochem 1997;245: 1–16.
  • Rossi JJ. Therapeutic applications of catalytic antisense RNAs (ribozymes). Ciba Found Symp 1997;209: 195–204.
  • Ohkawa J, Koguma T, Kohda T, Taira K. Ribozymes: from mechanistic studies to applications in vivo. J Biochem (Tokyo) 1995;118: 251–258.
  • Zaia JA, Chatterjee S, Wong KK, Elkins D, Taylor NR, Rossi JJ. Status of ribozyme and antisense-based developmental approaches for anti–HIV-1 therapy. Ann N Y Acad Sci 1992;660: 95–106.
  • Jankowsky E, Schwenzer B. Oligonucleotide facilitators may inhibit or activate a hammerhead ribozyme. Nucleic Acids Res 1996;24: 423–429.
  • Fell PL, Hudson AJ, Reynolds MA, Usman N, Akhtar S. Cellular uptake properties of a 2′-amino/2′-O-methyl–modified chimeric hammerhead ribozyme targeted to the epidermal growth factor receptor mRNA. Antisense Nucleic Acid Drug Dev 1997;7: 319–326.
  • Keck PJ, Hauser SD, Krivi G, Sanzo K, Warren T, Feder J, Connolly DT. Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science 1989;246: 1309–1312.
  • Pavco PA, Bouhana KS, Gallegos AM, Agrawal A, Blanchard KS, Grimm SL, Jensen KL, Andrews LE, Wincott FE, Pitot PA, Tressler RJ, Cushman C, Reynolds MA, Parry TJ. Antitumor and antimetastatic activity of ribozymes targeting the messenger RNA of vascular endothelial growth factor receptors. Clin Cancer Res 2000;6: 2094–2103.
  • Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, Pirotta N, Elfring GL, Miller LL. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000;343: 905–914.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.